Global Liver Institute
News
GLOBAL LIVER INSTITUTE
GLI’s Liver Action Network Supports World Obesity Day to Acknowledge Strong Connection Between NASH and Obesity
As members of Global Liver Institute’s Liver Action Network (LAN), the undersigned organizations are proud to take part in World Obesity Day, and take action to recognize the bidirectional relationship between many chronic liver diseases like nonalcoholic steatohepatitis (NASH), and obesity. Worldwide, NASH affects more than 148 million people and continues to rise each year.1 Increasing amounts…
Liver Action Network Announces New Partnership with Empire Liver Foundation
(Washington, D.C., March 2, 2022) – Global Liver Institute (GLI) proudly announces the expansion of the Liver Action Network (LAN) to include a partnership with Empire Liver Foundation. Based in New York City, this transformative organization provides clinical training to healthcare professionals on how to screen and treat patients with Hepatitis B & C in a variety of clinical settings. “Empire Liver Foundation…
Global Liver Institute Applauds the Confirmation of New Food and Drug Administration Commissioner Dr. Robert Califf
On Tuesday, February 15, the United States Senate confirmed Dr. Robert Califf to lead the Food and Drug Administration (FDA) in a 50-46 vote. For the last 13 months there has been a critical gap in permanent leadership at the FDA. During this extended break, especially during a global pandemic, we greatly appreciate Acting Commissioner Dr. Janet Woodcock’s guidance and service. However, withou…
Global Liver Institute Leads Second Annual Rare Liver Diseases Month
WASHINGTON, DC, FEBRUARY 1, 2022 – Global Liver Institute (GLI), a patient-led liver health nonprofit operating globally, is proud to announce today the launch of its second annual Rare Liver Diseases Month as part of its mission to improve the lives of individuals and families impacted by liver disease. The campaign, themed #RareAware, will feature an array of activities throughout February, including…
January Liver Health Policy Update
Rapid advancements to policy and committees welcomed in the new year. One of the most highlighted actions was the advancement of the nomination of Dr. Robert Califf as the incoming commissioner of the FDA to the full U.S. Senate. GLI and the patient advocacy…
New Year, Fresh Perspectives
I had the opportunity to participate in the NASH-TAG 2022 Conference in Park City, Utah. Thank you to course directors Michael Charlton, MBBS, FRCP; Vlad Ratziu, MD; Stephen Harrison, MD, and Rohit Loomba, MD, MHSc for setting a standard for high-quality scientific presentations, and even higher expectation and tone for collaboration and innovative thinking…
Good News, New Tools! Combatting COVID-19 in 2022
As we enter a third calendar year marked by COVID-19, the Omicron variant has caused pandemic peaks in cases and hospitalizations. However, we also have a greater understanding of the disease–and more tools at hand–than ever before. You may feel inundated with updated guidelines…
Global Liver Institute Announces New Leadership of GLI’s Liver Action Network
Washington, DC, January 14, 2022 – In 2021, the Global Liver Institute (GLI) formed the Liver Action Network (LAN) to better synchronize engagement across the liver advocacy community, and to meet the needs of a rapidly growing cadre of liver health advocates. The LAN operates as a first-of-its-kind network that provides community member organizations a central structure for the formulation…
Global Liver Institute and TriSalus Life Sciences Partner To Launch “Liver Central,” a New Resource Hub for Liver Cancer Researchers, Clinicians and Patients
The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life Sciences®, an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors, today announced the launch of Liver Central, a comprehensive online guide for…
Celebrating 2021 – Momentum Gained in NASH
In 2020, GLI and the GLI NASH Council released the U.S. NASH Action Plan to comprehensively address NASH and its impact on patients and families, public health, and the economy. The recommendations presented in the U.S. NASH Action Plan were developed to address critical actions necessary to stop the rise of this life-threatening disease. Issues include…
Liver Health Policy Update December 2021 – A Year of Advocacy in Review
In the past, efforts in liver advocacy were siloed by individual liver disease lessening their impact and limiting their effectiveness at shaping national health policy. In 2021 thanks to the efforts of Global Liver Institute (GLI), GLI’s newly created Liver Action Network (LAN), and collaboration throughout the liver advocacy community, we finally saw the value of synchronized engagement…
Global Liver Institute Holds Primary Biliary Cholangitis (PBC) Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting
On February 4, 2022 10 AM ET, Global Liver Institute will lead an Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) on Primary Biliary Cholangitis (PBC). This online event is open to the public with registration required.